New hope to shield kidneys in sickle cell disease
NCT ID NCT07175051
Summary
This study is testing if a medication called empagliflozin can slow or prevent kidney damage in adults with sickle cell anemia who show early signs of kidney problems. The drug is already approved to protect kidneys in other diseases. Researchers will enroll 20 participants to see if it improves specific markers of kidney health and blood flow over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALBUMINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois Chicago, Sickle Cell Center
Chicago, Illinois, 60302, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.